New editor of the NEJM said the author of this article was "undoubtedly brilliant."
November 3, 2026 at 7:08 PM
New editor of the NEJM said the author of this article was "undoubtedly brilliant."
In a new NEJM Voices blog post, @paulsaxmd.bsky.social tells us a little more about himself — and why he’s excited to lead NEJM Clinician. Read “A New Role for Me at NEJM” and sign up for email alerts: https://nej.md/4ztnVMS
November 4, 2026 at 2:00 PM
In a new NEJM Voices blog post, @paulsaxmd.bsky.social tells us a little more about himself — and why he’s excited to lead NEJM Clinician. Read “A New Role for Me at NEJM” and sign up for email alerts: https://nej.md/4ztnVMS
Becerra has both a JAMA and an NEJM… this is a cruel and desolate world…
November 4, 2026 at 7:24 AM
Becerra has both a JAMA and an NEJM… this is a cruel and desolate world…
Uusi kiinnostava RCT-tutkimus NEJM AI:ssa. Ennen vastaanottoa potilaille annetut tekoälyn tuottamat potilastiivistelmät paransivat potilaskokemusta ja lyhensivät vastaanottojen kestoa noin 21 %.
ai.nejm.org/doi/full/10....
#sote #AI #digipalvelut #vaikuttavuus #RCT
ai.nejm.org/doi/full/10....
#sote #AI #digipalvelut #vaikuttavuus #RCT
November 3, 2026 at 5:33 AM
Uusi kiinnostava RCT-tutkimus NEJM AI:ssa. Ennen vastaanottoa potilaille annetut tekoälyn tuottamat potilastiivistelmät paransivat potilaskokemusta ja lyhensivät vastaanottojen kestoa noin 21 %.
ai.nejm.org/doi/full/10....
#sote #AI #digipalvelut #vaikuttavuus #RCT
ai.nejm.org/doi/full/10....
#sote #AI #digipalvelut #vaikuttavuus #RCT
Hear Dr. Maria Abreu’s Phase 2b icotrokinra trial for ulcerative colitis featured on NEJM’s weekly podcast 🎙️ A once-daily oral pill outperformed placebo at week 12. Listen on Apple Podcasts or Spotify: www.nejm.org/do/10.1056/N... #IBD #UlcerativeColitis
NEJM This Week — October 15, 2026 | NEJM
Audio summary from the New England Journal of Medicine — NEJM This Week — October 15, 2026
www.nejm.org
November 4, 2026 at 9:07 PM
Hear Dr. Maria Abreu’s Phase 2b icotrokinra trial for ulcerative colitis featured on NEJM’s weekly podcast 🎙️ A once-daily oral pill outperformed placebo at week 12. Listen on Apple Podcasts or Spotify: www.nejm.org/do/10.1056/N... #IBD #UlcerativeColitis
Just wow. I remember people talking about therapies when DREADDs first arrived and thinking they were nuts.
Seriously wow and yay science 🧠🧪. While these are trying times, I have such optimism and excitement for where we are as a field.
www.nejm.org/doi/abs/10.1...
Seriously wow and yay science 🧠🧪. While these are trying times, I have such optimism and excitement for where we are as a field.
www.nejm.org/doi/abs/10.1...
Chemogenetic Neuromodulation for Refractory Epilepsy | NEJM
In three patients with refractory epilepsy, hippocampal chemogenetic therapy plus
low-dose clozapine was associated with a mean seizure-frequency reduction of 92.6%.
Adverse events were grade 1 or 2.
www.nejm.org
November 5, 2026 at 12:53 AM
Just wow. I remember people talking about therapies when DREADDs first arrived and thinking they were nuts.
Seriously wow and yay science 🧠🧪. While these are trying times, I have such optimism and excitement for where we are as a field.
www.nejm.org/doi/abs/10.1...
Seriously wow and yay science 🧠🧪. While these are trying times, I have such optimism and excitement for where we are as a field.
www.nejm.org/doi/abs/10.1...
DREADDs work in humans, wow, this is amazing stuff: www.nejm.org/doi/10.1056/... #neuroskyence
Chemogenetic Neuromodulation for Refractory Epilepsy | NEJM
In three patients with refractory epilepsy, hippocampal chemogenetic therapy plus
low-dose clozapine was associated with a mean seizure-frequency reduction of 92.6%.
Adverse events were grade 1 or 2.
www.nejm.org
November 5, 2026 at 8:34 AM
DREADDs work in humans, wow, this is amazing stuff: www.nejm.org/doi/10.1056/... #neuroskyence
In a new NEJM Voices blog post, Don Dizon, MD, reflects on grief and the importance of having our losses acknowledged. Read “Disenfranchised Grief” and sign up for email alerts: https://nej.md/4imrDSk
November 2, 2026 at 9:00 PM
In a new NEJM Voices blog post, Don Dizon, MD, reflects on grief and the importance of having our losses acknowledged. Read “Disenfranchised Grief” and sign up for email alerts: https://nej.md/4imrDSk
Fantastic piece in the NEJM pointing out that insurers use administrative burdens -- such as requiring preauthorizations and making physicians fill out increasing amounts of paperwork -- deliberately to increase their profits.
New @nejm.org Voices:
“Too often, clinicians want to give the benefit of the doubt and behave as if these are unintentional inefficiencies. Data are accumulating that show administrative burdens are anything but unintentional”
voices.nejm.org/doi/full/10....
“Too often, clinicians want to give the benefit of the doubt and behave as if these are unintentional inefficiencies. Data are accumulating that show administrative burdens are anything but unintentional”
voices.nejm.org/doi/full/10....
voices.nejm.org
October 30, 2026 at 6:24 PM
Fantastic piece in the NEJM pointing out that insurers use administrative burdens -- such as requiring preauthorizations and making physicians fill out increasing amounts of paperwork -- deliberately to increase their profits.
Study shows 4CMenB vaccine might cut N. gonorrhoeae cases. Randomized trial with 1,000 MSM, 2 doses vs. placebo. Promising results! 🚀 PMID:42418797, N Engl J Med 2026, @NEJM https://doi.org/10.1056/NEJMoa2516739 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://doi.org/10.1056/NEJMoa2516739
No description available
doi.org
November 5, 2026 at 3:00 AM
NEJM guidelines say no P values for secondary outcomes without a prespecified multiplicity plan. So why does POET II report P=0.04 for relapse? Did I miss something?
November 5, 2026 at 2:30 AM
NEJM guidelines say no P values for secondary outcomes without a prespecified multiplicity plan. So why does POET II report P=0.04 for relapse? Did I miss something?
Three major October headlines from studies published in NEJM:
1️⃣ Weight-loss drug could help address nighttime sleep disruptions for millions (FOX News) nej.md/3UTF6rN
Original Article: Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea (TRIUMPH-1 and -2) nej.md/4BmAHOI
1️⃣ Weight-loss drug could help address nighttime sleep disruptions for millions (FOX News) nej.md/3UTF6rN
Original Article: Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea (TRIUMPH-1 and -2) nej.md/4BmAHOI
November 3, 2026 at 7:00 PM
Three major October headlines from studies published in NEJM:
1️⃣ Weight-loss drug could help address nighttime sleep disruptions for millions (FOX News) nej.md/3UTF6rN
Original Article: Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea (TRIUMPH-1 and -2) nej.md/4BmAHOI
1️⃣ Weight-loss drug could help address nighttime sleep disruptions for millions (FOX News) nej.md/3UTF6rN
Original Article: Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea (TRIUMPH-1 and -2) nej.md/4BmAHOI
Could a single gene-editing therapy target a broad range of rare diseases? 2025–26 NEJM Editorial Fellow Katerina Lin, MD, explains the clinical implications of editing tRNA genes to broaden nonsense therapeutics. Go deeper on this subject: https://nej.md/4ttIiXg
November 1, 2026 at 2:01 PM
Could a single gene-editing therapy target a broad range of rare diseases? 2025–26 NEJM Editorial Fellow Katerina Lin, MD, explains the clinical implications of editing tRNA genes to broaden nonsense therapeutics. Go deeper on this subject: https://nej.md/4ttIiXg
People put DREADDs - designer receptors activated by a companion drug - in human brains for the first time, hoping to use them to control epilepsy. Preliminary results of a pilot study are out now in NEJM. It wasn't powered to test efficacy - but there are hints.
cen.acs.org/pharmaceutic...
cen.acs.org/pharmaceutic...
Designer receptor therapy long used in the lab crosses over into humans
Chemogenetics shows promise for treating epilepsy in pilot trial
cen.acs.org
November 4, 2026 at 10:02 PM
People put DREADDs - designer receptors activated by a companion drug - in human brains for the first time, hoping to use them to control epilepsy. Preliminary results of a pilot study are out now in NEJM. It wasn't powered to test efficacy - but there are hints.
cen.acs.org/pharmaceutic...
cen.acs.org/pharmaceutic...
NEJM Interviews
NEJM Interview: Anjali Deshmukh on legal challenges to fines issued by federal agencies.
NEJM Interviews · Episode
open.spotify.com
November 1, 2026 at 4:11 AM
NEJM Interviews
Le scanner coronarien, ce truc inutile en dépistage ciblé, j'ose pas imaginer en non ciblé. www.nejm.org/doi/full/10....
Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain | NEJM
Many patients with suspected acute coronary syndrome in whom myocardial infarction has been ruled out in the emergency department remain at risk for cardiovascular events. Whether further investiga...
www.nejm.org
November 5, 2026 at 5:01 AM
Le scanner coronarien, ce truc inutile en dépistage ciblé, j'ose pas imaginer en non ciblé. www.nejm.org/doi/full/10....
Gram-negative resistance continues to challenge clinicians worldwide. 🦠 A new NEJM review explores emerging resistance mechanisms, treatment options, and the critical role of rapid diagnostics and antimicrobial stewardship.
🔗
🔗
Gram-Negative Bacterial Resistance | NEJM
The rapid worldwide spread of antimicrobial resistance among gram-negative bacteria is driven by a complex interplay of human, environmental, and health care–associated factors and accelerated by m...
www.nejm.org
November 2, 2026 at 1:39 PM
Gram-negative resistance continues to challenge clinicians worldwide. 🦠 A new NEJM review explores emerging resistance mechanisms, treatment options, and the critical role of rapid diagnostics and antimicrobial stewardship.
🔗
🔗
Writing in a new Voices post, Dr. @iwashyna.bsky.social explains how administrative burdens have increasingly become nonfinancial barriers to providing best care and that it does not have to be this way. Read the latest from Dr. Iwashyna: https://nej.md/4igd3vK
November 2, 2026 at 1:11 AM
Writing in a new Voices post, Dr. @iwashyna.bsky.social explains how administrative burdens have increasingly become nonfinancial barriers to providing best care and that it does not have to be this way. Read the latest from Dr. Iwashyna: https://nej.md/4igd3vK
Read the latest Voices post from Dr. @iwashyna.bsky.social: Hassle as a Health Care Business Strategy https://nej.md/4igd3vK
November 3, 2026 at 12:05 PM
Read the latest Voices post from Dr. @iwashyna.bsky.social: Hassle as a Health Care Business Strategy https://nej.md/4igd3vK
🧬 Triglyceride drug cut pancreatitis
In two trials, 91% and 93% on plozasiran got blood fat under 500 mg per deciliter, against about half on placebo. Pancreatitis fell from 5 to 1 per 100 patient-years. Fewer painful attacks.
🔗 doi.org/10.1056/nejmoa2610014
#Medicine #Genetics 🧪
In two trials, 91% and 93% on plozasiran got blood fat under 500 mg per deciliter, against about half on placebo. Pancreatitis fell from 5 to 1 per 100 patient-years. Fewer painful attacks.
🔗 doi.org/10.1056/nejmoa2610014
#Medicine #Genetics 🧪
Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis | NEJM
Severe hypertriglyceridemia is associated with an increased risk of acute pancreatitis. Plozasiran, a small interfering RNA targeting APOC3 messenger RNA, lowers triglyceride levels and potentially...
doi.org
November 5, 2026 at 5:43 AM
🧬 Triglyceride drug cut pancreatitis
In two trials, 91% and 93% on plozasiran got blood fat under 500 mg per deciliter, against about half on placebo. Pancreatitis fell from 5 to 1 per 100 patient-years. Fewer painful attacks.
🔗 doi.org/10.1056/nejmoa2610014
#Medicine #Genetics 🧪
In two trials, 91% and 93% on plozasiran got blood fat under 500 mg per deciliter, against about half on placebo. Pancreatitis fell from 5 to 1 per 100 patient-years. Fewer painful attacks.
🔗 doi.org/10.1056/nejmoa2610014
#Medicine #Genetics 🧪
First instance of a study that
DREADDs can work in humans. This is not reporting a clinical trial, but a first-in-human pilot study.
www.nejm.org/doi/full/10....
DREADDs can work in humans. This is not reporting a clinical trial, but a first-in-human pilot study.
www.nejm.org/doi/full/10....
Chemogenetic Neuromodulation for Refractory Epilepsy | NEJM
In three patients with refractory epilepsy, hippocampal chemogenetic therapy plus low-dose clozapine was associated with a mean seizure-frequency reduction of 92.6%. Adverse events were grade 1 or 2.
www.nejm.org
November 5, 2026 at 4:43 AM
First instance of a study that
DREADDs can work in humans. This is not reporting a clinical trial, but a first-in-human pilot study.
www.nejm.org/doi/full/10....
DREADDs can work in humans. This is not reporting a clinical trial, but a first-in-human pilot study.
www.nejm.org/doi/full/10....